TG Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:TGTX)

Analyst Price Target for TGTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$64.00

▲ +45.82% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for TG Therapeutics in the last 3 months. The average price target is $64.00, with a high forecast of $95.00 and a low forecast of $38.00. The average price target represents a 45.82% upside from the last price of $43.89.

Buy

The current consensus among 5 polled investment analysts is to buy stock in TG Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/5/2019

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/4/2019

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/3/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/1/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/30/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/28/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/27/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/26/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/8/2021	HC Wainwright	Boost Price Target	Buy	$78.00 ➝ $79.00	Medium	i
2/5/2021	B. Riley	Boost Price Target	Buy	$90.00 ➝ $95.00	High	i Rating by Mayank Mamtani at B. Riley
1/19/2021	HC Wainwright	Boost Price Target	Buy	$61.00 ➝ $78.00	Low	i
12/10/2020	HC Wainwright	Boost Price Target	Buy	$38.00 ➝ $61.00	High	i
10/28/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$30.00 ➝ $48.00	Low	i
9/1/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$38.00	High	i
8/11/2020	HC Wainwright	Boost Price Target	Buy	$32.00 ➝ $38.00	Medium	i Rating by Edward White at HC Wainwright
8/10/2020	B. Riley	Reiterated Rating	Buy	$37.00	Medium	i Rating by Mayank Mamtani at B. Riley
6/15/2020	B. Riley	Reiterated Rating	Buy	$37.00	Low	i Rating by Mayank Mamtani at B. Riley
6/5/2020	Evercore ISI	Initiated Coverage	Outperform	$60.00	High	i
6/1/2020	B. Riley	Reiterated Rating	Buy	$37.00	High	i Rating by Mayank Mamtani at B. Riley
5/29/2020	HC Wainwright	Reiterated Rating	Buy		High	i Rating by Edward White at HC Wainwright
5/18/2020	HC Wainwright	Reiterated Rating	Buy	$32.00	Medium	i Rating by Edward White at HC Wainwright
5/17/2020	B. Riley	Boost Price Target	Buy	$29.00 ➝ $37.00	Medium	i Rating by Mayank Mamtani at B. Riley
5/12/2020	HC Wainwright	Reiterated Rating	Buy	$32.00	Medium	i Rating by Edward White at HC Wainwright
5/6/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$19.00 ➝ $35.00	High	i
5/6/2020	B. Riley	Boost Price Target	Buy	$25.00 ➝ $29.00	High	i Rating by Mayank Mamtani at B. Riley
5/5/2020	HC Wainwright	Boost Price Target	Buy	$24.00 ➝ $32.00	High	i Rating by Edward White at HC Wainwright
4/17/2020	B. Riley	Reiterated Rating	Buy	$25.00	High	i Rating by Mayank Mamtani at B. Riley
1/17/2020	HC Wainwright	Boost Price Target	Buy	$20.00 ➝ $24.00	High	i Rating by Edward White at HC Wainwright
12/10/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	High	i
11/27/2019	B. Riley	Initiated Coverage	Buy	$12.00	High	i Rating by Mayank Mamtani at B. Riley
11/12/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	Medium	i
10/28/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	Medium	i
6/11/2019	B. Riley	Reiterated Rating	Buy		Medium	i Rating by H. Polishetty at B. Riley
5/13/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	High	i Rating by A. Young at Cantor Fitzgerald
4/12/2019	HC Wainwright	Reiterated Rating	Buy	$20.00	Low	i
3/29/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$17.00	High	i Rating by A. Young at Cantor Fitzgerald
2/6/2019	Jefferies Financial Group	Reiterated Rating	Buy	$8.00	High	i
1/22/2019	HC Wainwright	Reiterated Rating	Buy		High	i
1/8/2019	B. Riley	Initiated Coverage	Buy	$10.00	Low	i
11/12/2018	HC Wainwright	Reiterated Rating	Buy	$20.00	High	i
11/2/2018	HC Wainwright	Reiterated Rating	Buy	$21.00	Medium	i
9/26/2018	LADENBURG THALM/SH SH	Set Price Target	Buy	$27.00	N/A	i Rating by Matthew Kaplan at LADENBURG THALM/SH SH
9/25/2018	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$22.00 ➝ $12.00	High	i
8/7/2018	HC Wainwright	Reiterated Rating	Buy	$38.00	High	i
4/25/2018	Raymond James	Reiterated Rating	Buy		Low	i Rating by Reni Benjamin at Raymond James
4/19/2018	Raymond James	Reiterated Rating	Buy		Low	i Rating by Reni Benjamin at Raymond James
3/9/2018	B. Riley	Reiterated Rating	Buy ➝ Buy	$21.50 ➝ $27.00	Medium	i Rating by M. Kumar at B. Riley
1/17/2018	B. Riley	Reiterated Rating	Buy	$21.50	Low	i Rating by M. Kumar at B. Riley
1/16/2018	HC Wainwright	Reiterated Rating	Buy	$33.00	Low	i Rating by E. White at HC Wainwright
1/8/2018	HC Wainwright	Reiterated Rating	Buy	$33.00	Low	i Rating by E. White at HC Wainwright
12/12/2017	Raymond James	Reiterated Rating	Buy		Low	i Rating by Reni Benjamin at Raymond James
12/11/2017	HC Wainwright	Reiterated Rating	Buy	$33.00	High	i Rating by E. White at HC Wainwright
12/11/2017	B. Riley	Reiterated Rating	Buy	$21.50	High	i Rating by M. Kumar at B. Riley
12/1/2017	B. Riley	Initiated Coverage	Buy ➝ Buy	$21.50	High	i Rating by M. Kumar at B. Riley
11/14/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $33.00	N/A	i Rating by E. White at HC Wainwright
10/3/2017	SunTrust Banks	Reiterated Rating	Buy	$28.00	Medium	i
6/17/2017	(FBRC)	Reiterated Rating	Buy		Low	i Rating by Edward White at (FBRC)
6/5/2017	Jefferies Financial Group	Reiterated Rating	Buy	$23.00	Medium	i
5/18/2017	(FBRC)	Reiterated Rating	Buy		Low	i Rating by Edward White at (FBRC)
5/1/2017	(FBRC)	Reiterated Rating	Buy		Low	i Rating by Edward White at (FBRC)
4/25/2017	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$23.00	High	i
4/21/2017	Raymond James	Reiterated Rating	Buy		High	i Rating by Reni Benjamin at Raymond James
3/13/2017	SunTrust Banks	Set Price Target	Buy	$28.00	Low	i Rating by Yatin Suneja at SunTrust Banks, Inc.
3/8/2017	LADENBURG THALM/SH SH	Set Price Target	Buy	$30.00	Low	i Rating by Matthew Kaplan at LADENBURG THALM/SH SH
3/7/2017	HC Wainwright	Reiterated Rating	Buy	$18.00	N/A	i
3/7/2017	Langenberg & Company	Boost Price Target	Positive	$28.00 ➝ $30.00	N/A	i
3/6/2017	(FBRC)	Reiterated Rating	Outperform ➝ Outperform	$24.00 ➝ $26.00	N/A	i Rating by Edward White at (FBRC)
2/22/2017	Aegis	Initiated Coverage	Buy	$26.00	N/A	i
12/7/2016	Roth Capital	Set Price Target	Buy	$33.00	N/A	i Rating by Joseph Pantginis at Roth Capital
12/6/2016	(FBRC)	Set Price Target	Buy	$24.00	N/A	i Rating by Edward White at (FBRC)
11/8/2016	Roth Capital	Reiterated Rating	Buy	$33.00	N/A	i Rating by Joseph Pantginis at Roth Capital
10/27/2016	Roth Capital	Set Price Target	Buy	$33.00	N/A	i Rating by Joseph Pantginis at Roth Capital
10/20/2016	Roth Capital	Set Price Target	Buy	$33.00	N/A	i Rating by Joseph Pantginis at Roth Capital
10/15/2016	HC Wainwright	Reiterated Rating	Buy	$22.00 ➝ $18.00	N/A	i
10/15/2016	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$28.00	N/A	i
10/14/2016	Roth Capital	Reiterated Rating	Buy	$33.00	N/A	i
10/6/2016	Brean Capital	Reiterated Rating	Buy	$28.00	N/A	i Rating by Jonathan Aschoff at Brean Capital
9/19/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Edward White at (FBRC)
8/24/2016	S&P Equity Research	Lower Price Target		$7.15 ➝ $6.40	N/A	i
8/10/2016	Roth Capital	Reiterated Rating	Buy	$33.00	N/A	i Rating by Joseph Pantginis at Roth Capital
6/13/2016	Brean Capital	Reiterated Rating	Buy		N/A	i Rating by Jonathan Aschoff at Brean Capital
6/13/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Edward White at (FBRC)
6/9/2016	Roth Capital	Reiterated Rating	Buy	$33.00	N/A	i Rating by Joseph Pantginis at Roth Capital
6/7/2016	Brean Capital	Reiterated Rating	Buy		N/A	i Rating by Jonathan Aschoff at Brean Capital
5/31/2016	Brean Capital	Reiterated Rating	Buy		N/A	i Rating by Jonathan Aschoff at Brean Capital
5/27/2016	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$7.22 ➝ $18.00	N/A	i
5/19/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Edward White at (FBRC)
5/4/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Edward White at (FBRC)
4/14/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Edward White at (FBRC)
3/10/2016	HC Wainwright	Reiterated Rating	Buy	$22.00	N/A	i
3/8/2016	Roth Capital	Reiterated Rating	Buy	$33.00	N/A	i Rating by Joseph Pantginis at Roth Capital
3/8/2016	Brean Capital	Reiterated Rating	Buy	$28.00	N/A	i Rating by Jonathan Aschoff at Brean Capital

(Data available from 2/26/2016 forward)

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. is headquartered in New York, New York.

Today's Range

Now: $43.89

$42.57

$44.79

50 Day Range

MA: $49.56

$44.73

$54.30

52 Week Range

Now: $43.89

$6.34

$56.74

Volume

13,667 shs

Average Volume

1,550,894 shs

Market Capitalization

$5.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28

Frequently Asked Questions

What sell-side analysts currently cover shares of TG Therapeutics?

The following Wall Street sell-side analysts have issued reports on TG Therapeutics in the last year: B. Riley, Cantor Fitzgerald, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., and Zacks Investment Research.
View the latest analyst ratings for TGTX.

What is the current price target for TG Therapeutics?

5 Wall Street analysts have set twelve-month price targets for TG Therapeutics in the last year. Their average twelve-month price target is $64.00, suggesting a possible upside of 44.4%. B. Riley has the highest price target set, predicting TGTX will reach $95.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $38.00 for TG Therapeutics in the next year.
View the latest price targets for TGTX.

What is the current consensus analyst rating for TG Therapeutics?

TG Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TGTX will outperform the market and that investors should add to their positions of TG Therapeutics.
View the latest ratings for TGTX.

What other companies compete with TG Therapeutics?

Other companies that are similar to TG Therapeutics include Genmab A/S, Genmab A/S, MERCK Kommanditgesellschaft auf Aktien, Horizon Therapeutics Public, UCB, Catalent, CureVac, Royalty Pharma, Alnylam Pharmaceuticals, Ono Pharmaceutical, BioMarin Pharmaceutical, Elanco Animal Health, Teva Pharmaceutical Industries, Bausch Health Companies and Grifols.

How do I contact TG Therapeutics' investor relations team?

TG Therapeutics' physical mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company's listed phone number is 212-554-4484 and its investor relations email address is [email protected] The official website for TG Therapeutics is www.tgtherapeutics.com.

NASDAQ:TGTX - TG Therapeutics Stock Price Target and Predictions

Analyst Price Target for TGTX

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of TG Therapeutics?

What is the current price target for TG Therapeutics?

What is the current consensus analyst rating for TG Therapeutics?

What other companies compete with TG Therapeutics?

How do I contact TG Therapeutics' investor relations team?